Addendum
Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15
Report documents
-
Addendum
Daratumumab (newly diagnosed multiple myeloma, stem cell transplant suitable) - Addendum to Commission A20-15
Dossier assessment
Indication:
Adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant
Result of dossier assessment:
Conclusion of dossier assessment A20-15 unchanged
Additional information
Federal Joint Committee (G-BA)
2020-08-20: G-BA decision was published.
Project details
- Project no.
- A20-50
- Commission
- Commission awarded on 20.08.2020 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides
on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Daratumumab (multiple myeloma, stem cell transplant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed